Short answer
FATE THERAPEUTICS INC (FATE) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces Fate Therapeutics’ financial results for quarter ended September 30, 2026.
FATE THERAPEUTICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces Fate Therapeutics’ financial results for quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed financial results for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q3 net loss $30.7M, or $0.25 per share, versus $32.3M, or $0.27, in Q3 2025
- Cash, equivalents and investments $139.1M, with $15.0M CIRM grant extending runway to mid-2028
- FT819 safety across 29 autoimmune patients: no dose-limiting toxicities, ICANS, GvHD or deaths
- RECLAIM-LN Phase 2 opened across 17 sites, targeting approximately 53 patients with Week 26 renal response endpoint
- FT839 COMPLETE trial sites activated, with patient dosing expected by year-end in autoimmune disease including rheumatoid arthritis
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other FATE THERAPEUTICS INC 8-K filings
Get the next FATE 8-K as it lands
Follow FATE for push alerts, or ask the research agent what this filing means.